Nonactin |
| Katalog-Nr.GC12090 |
Nonactin ist ein natÜrlich vorkommendes Makrotetrolid-Antibiotikum aus Streptomyces griseus.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 6833-84-7
Sample solution is provided at 25 µL, 10mM.
Nonactin is a macrotetrolide antibiotic and mitochondrial oxidative phosphorylation uncoupler[1][2]. Nonactin inhibits recombinant human adenine nucleotide translocase (ANT) isoforms ANT1–4 with IC50 values of 4.4, 3.3, 4.7, and 3.3μM, respectively[3]. Nonactin is commonly used in studies of oxidative-phosphorylation uncoupling, ionophore mechanisms, and apoptosis in β-catenin-mutant tumors[4].
In vitro, treatment of BHK cells with Nonactin (5μg/ml; 12-14h) blocks cell-surface expression of NDV-HN and VSV-G glycoproteins without reducing their total synthesis, causes intracellular accumulation of VSV-G, inhibits syncytium formation and lowers infectious-virus yield[5]. Treatment of medullary thyroid carcinoma TT cells with Nonactin (0.12-0.5µM; 72h) reduces RET protein and mRNA level, suppresses pAKT/pmTOR signaling, induces G1 arrest, lowers cyclin D1/E, E2F1 and BCL-2, increases γH2AX and cleaved PARP, and elevates caspase-3/7 activity[6].
In vivo, Nonactin (100mg/kg/day; i.p.; 4 days) induced marked tumor regression and robust TUNEL-positive apoptosis in β-catenin-mutant HCT 116 xenograft mice without significant body-weight loss[7].
References:
[1] Pampaloni F, Mayer B, Kabat Vel-Job K, et al. A Novel Cellular Spheroid-Based Autophagy Screen Applying Live Fluorescence Microscopy Identifies Nonactin as a Strong Inducer of Autophagosomal Turnover. SLAS Discov. 2017;22(5):558-570.
[2] Martínez-Haya B, Avilés-Moreno JR, Hamad S, Elguero J. On the ionophoric selectivity of nonactin and related macrotetrolide derivatives. Phys Chem Chem Phys. 2017;19(2):1288-1297.
[3] Zhang Y, Tian D, Matsuyama H, et al. Human Adenine Nucleotide Translocase (ANT) Modulators Identified by High-Throughput Screening of Transgenic Yeast. J Biomol Screen. 2016;21(4):381-390.
[4] Hu J, Zhang J, He J. Structures, Synthesis and Biological Activities of Nonactic Acid and Its Derivatives. Curr Med Chem. 2021;28(42):8673-8691.
[5] Lee JM, Kim JG, Kim TH, et al. Nonactin hinders intracellular glycosylation in virus-infected baby hamster kidney cells. Mol Med Rep. 2010;3(1):115-119.
[6] Alqahtani T, Alsubait A, Aloumi M, et al. A novel role for nonactin: interfering with G-quadruplex in RET-driven medullary thyroid cancer. BMC Cancer. 2024;24(1):1569.
[7] Shikata Y, Kiga M, Futamura Y, et al. Mitochondrial uncoupler exerts a synthetic lethal effect against β-catenin mutant tumor cells. Cancer Sci. 2017;108(4):772-784.
| Cell experiment [1]: | |
Cell lines | MTC-derived TT cells |
Preparation Method | The MTC-derived TT cells were cultured in DMEM/F12 medium enriched with 15% heat-inactivated fetal bovine serum (FBS) and maintained under a humidified atmosphere with 5% CO2 at 37°C. Cells were plated at 7,500 cells per well in a 96-well plate and allowed to adhere overnight. Following this, they were exposed to various concentrations of Nonactin (0.12-0.5µM) for up to 72h. To evaluate cell viability, a solution of 0.33mg/mL MTS dye mixed with 200µg/mL phenazine methosulfate (PMS) was used. Absorbance readings were taken at 490nm. Caspase-3 activity in TT cells was evaluated utilizing the ApoAlert Caspase Fluorescent Assay kit. And cells were collected for PCR and Western blot analyses. |
Reaction Conditions | 0.12-0.5µM; 72h |
Applications | Treatment of medullary thyroid carcinoma TT cells with Nonactin reduces RET protein and mRNA level, suppresses pAKT/pmTOR signaling, lowers cyclin D1/E, E2F1 and BCL-2, increases γH2AX and cleaved PARP, and elevates caspase-3/7 activity. |
| Animal experiment [2]: | |
Animal models | BALB/cA Jcl-nu mice |
Preparation Method | Specific pathogen-free female nude mice (BALB/cA Jcl-nu) were used in this experiment. β-catenin-mutant HCT 116 cells (2×106cells/mL) were inoculated subcutaneously into the axillar region of the nude mice on Day 0. Nonactin was dissolved in 10% dimethylacetamide, 10% NIKKOL HCO60, and saline and given daily to the animals by intraperitoneal administration (100mg/kg). Tumor-bearing nude mice were randomly grouped (six mice/group), and administration of nonactin started on Day 9 to Day 12. Tumor volumes were calculated using a microgauge according to the following equations: Tumor volume (mm3)=1/2×(tumor length)×(tumor width)2. TUNEL staining of xenograft tumor tissue was performed using the FragEL DNA Fragmentation Detection Kit according to the manufacturer’s protocol. Tissue sections were viewed at 100×magnification, and images were captured with a digital camera. |
Dosage form | 100mg/kg/day; i.p.; 4 days |
Applications | Nonactin (100mg/kg/day; i.p.; 4 days) induced marked tumor regression and robust TUNEL-positive apoptosis in β-catenin-mutant HCT 116 xenograft mice without significant body-weight loss[7]. |
References: | |
| Cas No. | 6833-84-7 | SDF | |
| Chemical Name | (1R,2R,5R,7R,10S,11S,14S,16S,19R,20R,23R,25R,28S,29S,32S,34S)-2,5,11,14,20,23,29,32-octamethyl-4,13,22,31,37,38,39,40-octaoxapentacyclo[32.2.1.17,10.116,19.125,28]tetracontane-3,12,21,30-tetrone | ||
| Canonical SMILES | O=C([C@H](C)[C@@H]1O[C@H]2CC1)O[C@H](C)C[C@@H]3O[C@H]([C@H](C)C(O[C@@H](C)C[C@H]4O[C@@H]([C@@H](C)C(O[C@H](C)C[C@@H]5O[C@H]([C@H](C)C(O[C@@H](C)C2)=O)CC5)=O)CC4)=O)CC3 | ||
| Formula | C40H64O12 | M.Wt | 736.94 |
| Löslichkeit | 1mg/mL in ethanol, 0.25mg/mL in DMSO, 10mg/mL in DMF | Storage | Desiccate at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.357 mL | 6.7848 mL | 13.5696 mL |
| 5 mM | 271.4 μL | 1.357 mL | 2.7139 mL |
| 10 mM | 135.7 μL | 678.5 μL | 1.357 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 40 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *















